EXHIBIT 4.1 NOTE PURCHASE AGREEMENT This Note Purchase Agreement (this "Agreement") is made as of April 23, 2004 (the "Closing Date") by and between Ceptor Corporation, a Delaware corporation (the "Company"), and the persons or entities listed as...Note Purchase Agreement • May 28th, 2004 • Xechem International Inc • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledMay 28th, 2004 Company Industry Jurisdiction
EXHIBIT 4.3 WAIVER OF RIGHTS UNDER NOTE The undersigned holders of Notes of Ceptor Corporation are party to a certain Note Agreement (the "Note") and Note Purchase Agreement ("Purchase Agreement") by and among Ceptor Corporation, Xechem International,...Note Waiver Agreement • May 28th, 2004 • Xechem International Inc • Biological products, (no disgnostic substances)
Contract Type FiledMay 28th, 2004 Company Industry
EXHIBIT 4.4 WAIVER OF CONTINGENT CONSIDERATION The undersigned party to a Merger Agreement dated as of December 23, 2003 by and between Xechem International, Inc. ("Xechem"), Ceptor Acquisition, Inc., and Ceptor Corporation (the "Merger Agreement")...Waiver of Contingent Consideration • May 28th, 2004 • Xechem International Inc • Biological products, (no disgnostic substances)
Contract Type FiledMay 28th, 2004 Company IndustryThe undersigned party to a Merger Agreement dated as of December 23, 2003 by and between Xechem International, Inc. ("Xechem"), Ceptor Acquisition, Inc., and Ceptor Corporation (the "Merger Agreement") pursuant to which, in Section 1.7 thereof, the undersigned is entitled to payment of certain Contingent Consideration upon the occurrence of certain Award Events, as such terms are defined in the Merger Agreement. The undersigned hereby represents and warrants that he has neither pledged or assigned his rights in the Contingent Consideration and hereby waives and releases Xechem from any and all obligation with respect to payment of the Contingent Consideration on the basis of the representation of Ceptor to provide the undersigned with reasonably equivalent benefits, provided, however, that such benefits shall be payable in shares of the common stock of Ceptor, and that such release of Xechem is not conditioned upon Ceptor's provision of such replacement benefits or that the undersigned